Document Detail

Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies.
MedLine Citation:
PMID:  19640853     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Adiponectin is an anti-inflammatory and potentially antiatherogenic molecule. Some recent reports suggest that tumour necrosis factor alpha (TNFalpha) blockade therapy increases circulating adiponectin levels, but data are sparse and inconsistent.
METHODS: Data from a double-blind placebo controlled study of onercept in 126 patients with psoriatic arthritis (PsA) and from pre- and post-adalimumab treatment in 171 patients with rheumatoid arthritis (RA) were used to examine the effect of TNFalpha blockade therapy on adiponectin.
RESULTS: Despite expected associations of adiponectin with gender and baseline high-density lipoprotein cholesterol and triglyceride, adiponectin levels did not change over time with TNFalpha blockade therapy in either group. The mean+/-SD absolute change in adiponectin levels was -0.23+/-4.6 microg/ml in patients with PsA treated with combined onercept 50 mg and onercept 100 mg (vs placebo, p=0.60) and 0.28+/-3.23 microg/ml in patients with RA treated with adalimumab (vs baseline, p=0.66).
CONCLUSION: These results do not support a significant effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease.
Mike J L Peters; Pauline Watt; Lynne Cherry; Paul Welsh; Eric Henninger; Ben A C Dijkmans; Iain B McInnes; Michael T Nurmohamed; Naveed Sattar
Related Documents :
2234843 - Hla associations and ancestry in vogt-koyanagi-harada disease and sympathetic ophthalmia.
23837643 - Cerebrospinal flt3 ligand correlates to tau protein levels in primary sjögren's syndrome.
9880203 - Comparison of angiographic findings, risk factors, and long term follow-up between youn...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-07-28
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  69     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-11     Completed Date:  2010-09-07     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1687-90     Citation Subset:  IM    
Department of Rheumatology, VU University Medical Center, Amsterdam, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adiponectin / blood*
Antibodies, Monoclonal / pharmacology,  therapeutic use
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / pharmacology*,  therapeutic use
Arthritis, Psoriatic / blood*,  complications,  drug therapy
Arthritis, Rheumatoid / blood,  complications,  drug therapy
Autoimmune Diseases / blood*,  complications,  drug therapy
Cardiovascular Diseases / etiology
Epidemiologic Methods
Lipids / blood
Middle Aged
Receptors, Tumor Necrosis Factor, Type I / pharmacology,  therapeutic use
Tumor Necrosis Factor Decoy Receptors / pharmacology,  therapeutic use
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Adiponectin; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Lipids; 0/Receptors, Tumor Necrosis Factor, Type I; 0/Tumor Necrosis Factor Decoy Receptors; 0/Tumor Necrosis Factor-alpha; 0/recombinant human tumor necrosis factor-binding protein-1; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outside the unusual cell wall of the hyperthermophilic archaeon Aeropyrum pernix K1.
Next Document:  Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systemat...